The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...

Amgen reported yesterday that full-year 2023 sales of Lumakras were $280 million, a dip on the prior year, while Mirati ... KRAS category comes shortly after AstraZeneca licensed a KRAS G12D ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...

Silexion Therapeutics (SLXN ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor ...

NEW YORK--(BUSINESS WIRE)--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ ... In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy ...

Next: Access Our New, Shockingly Simple 'Alert System' Silexion Therapeutics Corp. SLXN revealed ... pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in ...

Shares of Silexion Therapeutics surged after the company ... when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer ...

The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan ...